Inositol Polyphosphate Inhibits Vascular Calcification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack an effective solution for reducing or preventing vascular calcification, a major contributor to cardiovascular diseases and mortality in patients with chronic kidney disease, as there is no approved treatment to inhibit the progression of primary calciprotein particles to secondary particles that lead to pathological crystallization.
Innovation Solution
The use of inositol phosphates, sulfates, and/or thiophosphates, potentially combined with poly(ethylene glycol) or polyglycerol, to prevent or reduce pathological crystallization in soft tissues by inhibiting the formation and adherence of calcium salt crystals, thereby addressing the underlying pathophysiological mechanisms of vascular calcification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no therapeutic intervention is applied, then vascular calcification progresses leading to arterial stiffening and cardiovascular disease, but current therapies lack effective solutions to inhibit the progression of calciprotein particles
Solution Approach 1:
The patent employs inositol polyphosphate compounds as intermediary substances that mediate between the harmful calcification process and the protective physiological state. These compounds act as molecular mediators that interfere with the maturation of calciprotein particles, preventing the transition from primary to secondary particles that would otherwise lead to pathological crystallization and vascular calcification.
Solution Approach 2:
The invention leverages the body's existing biochemical pathways and natural compounds (inositol polyphosphates that occur endogenously) to achieve therapeutic effect. By utilizing and enhancing the body's own biochemical mechanisms rather than introducing entirely foreign substances, the treatment aligns with self-service principles, allowing the physiological system to work against its own pathogenic processes.
2Object-affected harmful factors
If inositol polyphosphate compounds are administered to inhibit calcification, then progression of vascular calcification is reduced, but the mechanism involves complex interaction with calciprotein particle maturation processes
Solution Approach 1:
The patent extracts and isolates the specific functional mechanism responsible for calcification inhibition - the ability of inositol polyphosphate compounds to prevent the maturation transition of calciprotein particles. By focusing on this extracted mechanism rather than attempting to address all aspects of vascular calcification simultaneously, the treatment achieves targeted efficacy while managing mechanistic complexity.
Solution Approach 2:
The invention exploits parameter changes in the biochemical environment - specifically changes in the molecular composition and structural properties of calciprotein particles when inositol polyphosphates are present. By altering key parameters such as particle maturation rate, crystal formation kinetics, and calcium-phosphate precipitation dynamics, the treatment achieves therapeutic effect through controlled parameter modification rather than complex multi-component mechanisms.
3Stability of the object's composition
If primary calciprotein particles are allowed to mature into secondary particles, then natural physiological process occurs, but this leads to pathological crystallization and tissue damage
Solution Approach 1:
The patent applies preliminary anti-action by administering inositol polyphosphate compounds that preemptively inhibit the maturation process of calciprotein particles before they can transition from the benign primary state to the pathological secondary state. This preliminary intervention prevents the harmful transformation from occurring in the first place, rather than attempting to reverse or manage damage after crystallization has begun.
Solution Approach 2:
The invention implements preliminary action by establishing a protective biochemical environment through inositol polyphosphate administration before pathological calcification can establish itself. The compounds are present in advance to modify the maturation kinetics of calciprotein particles, ensuring that even when calcium and phosphate levels fluctuate, the particles remain in a stable, non-crystallizing state rather than progressing to harmful secondary particles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution effectively stops the formation and adherence of calcium phosphate precipitates, providing a dual mode of action that protects cells from damage and reduces the progression of vascular calcification, as demonstrated by in vitro and in vivo studies, showing potential therapeutic benefits for chronic kidney disease and associated cardiovascular issues.
Implementation Method 1
The use of inositol phosphates, sulfates, and/or thiophosphates, potentially combined with poly(ethylene glycol) or polyglycerol, to prevent or reduce pathological crystallization in soft tissues by inhibiting the formation and adherence of calcium salt crystals
Implementation Method 2
Blood components such as fetuin-A interact with calcium and phosphate to form soluble nanoparticles termed calciprotein particles (CPPs) that prevent precipitation and resultant calcification under normal conditions
Implementation Method 3
So-called primary CPPs are amorphous and have a hydrodynamic radius of typically less than 100 nm and mature with time to reorganize into crystalline secondary CPPs that have a hydrodynamic radius of more than 100 nm
Data Source
AI summary
Provided herein is an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.